Compare Palo Alto Networks Inc (PANW) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Palo Alto Networks Inc vs Zimmer Biomet Holdings Inc — how do they compare? Palo Alto Networks Inc trades at $418.78 (market cap $331.76B), while Zimmer Biomet Holdings Inc trades at $89.14 (market cap $16.95B). The key difference: Palo Alto Networks Inc is far larger — about 19.6× Zimmer Biomet Holdings Inc's market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while Palo Alto Networks Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Palo Alto Networks Inc for 82 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| PANW | ZBH | |
|---|---|---|
Market Cap | $331.76B | $16.95B |
Volume | 3,886,927 | 2,505,240 |
Sector | Technology | Health |
52-Week High | $419.91 | $103.98 |
52-Week Low | $141.67 | $79.58 |
Typical Hold Time | 82 Days | 89 Days |
Enterprise Value | $331.19B | $24.02B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Palo Alto Networks trades at $398.50, down 1.7% today but remains near recent highs. The stock shows strong technical momentum with bullish moving averages and has beaten earnings estimates for three consecutive quarters. Revenue growth continues at $9.22 billion for 2025, though profitability metrics show mixed results with high gross margins but modest net income margins. The company's AI security initiatives are driving positive media coverage and investor optimism.
Outlook remains positive given strong analyst consensus (72% buy ratings) and AI-driven cybersecurity demand, but premium valuations and execution risks warrant caution. The stock trades near its consensus price target of $398.70, suggesting limited near-term upside without significant earnings acceleration or multiple expansion.
Zimmer Biomet (ZBH) trades at $88.91, up 0.47% today, with a bearish technical signal from moving averages. The company reported Q2 2026 EPS of $2.07, beating estimates, and raised its 2026 outlook. Revenue growth remains steady, with 2025 revenue at $8.23B, though net income margin declined to 8.56%. The stock is supported by a quarterly dividend of $0.24 and a consensus price target of $103.11, suggesting potential upside.
The outlook is mixed: strong fundamentals and analyst optimism contrast with technical weakness. Investment opportunities include consistent earnings beats and dividend income, but risks involve rising debt levels and competitive pressures in the medical technology sector. The stock's current valuation at a P/E of 21.57 appears reasonable if growth continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Palo Alto Networks Inc
Palo Alto Networks is a pure-play cybersecurity vendor that sells security appliances, subscriptions, and support into enterprises, government entities, and service providers. The company's product portfolio includes firewall appliances, virtual firewalls, endpoint protection, cloud security, and cybersecurity analytics. The Santa Clara, California, firm was established in 2005 and sells its products worldwide.
Read more on PANW →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
